The Humira patent thicket, the Noerr–Pennington doctrine and antitrust’s patent problem

The Humira patent thicket, the Noerr–Pennington doctrine and antitrust’s patent problem

A recent federal appellate court decision will make challenging future pharmaceutical ‘patent thickets’ an uphill battle.

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Nature biotechnology 2022-12, Vol.40 (12), p.1761-1763
Hauptverfasser: Knox, Ryan, Curfman, Gregory
Format: Artikel
Sprache:eng
Schlagworte:
706/689/159
706/689/280
Adalimumab
Agriculture
Antitrust
Bioinformatics
Biological products
Biomedical and Life Sciences
Biomedical Engineering/Biotechnology
Biomedicine
Biotechnology
Competition
Decision making
District courts
FDA approval
Federal court decisions
First Amendment-US
Life Sciences
Litigation
Market entry
Petitions
State court decisions
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:A recent federal appellate court decision will make challenging future pharmaceutical ‘patent thickets’ an uphill battle.
ISSN:1087-0156
1546-1696
DOI:10.1038/s41587-022-01583-w